vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Below 50-Day Moving Average – What’s Next?

vTv Therapeutics Inc. (NASDAQ:VTVT) passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $32.37 and traded as low as $31.07. vTv Therapeutics shares last traded at $31.10, with a volume of 11,170 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on VTVT shares. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. HC Wainwright lowered their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, BTIG Research increased their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Stock Up 0.5%

The firm’s 50 day moving average is $32.30 and its 200 day moving average is $34.06. The firm has a market capitalization of $121.08 million, a price-to-earnings ratio of -28.99 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, sell-side analysts predict that vTv Therapeutics Inc. will post -2.35 earnings per share for the current year.

vTv Therapeutics Company Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company’s research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.